Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency

• Published in: Transplantation proceedings 2003-12, Vol.35 (8), p.3029-3031
• Main Authors: Neff, G.W, Montalbano, M, Slapak-Green, G, Meyer, D, Berney, T, Safdar, K, Schiff, E.R, Tzakis, A.G
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Creatinine - blood; Drug toxicity and drugs side effects treatment; Female; Humans; Immunomodulators; Immunosuppressive Agents - therapeutic use; Liver Transplantation - immunology; Liver Transplantation - physiology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Postoperative Complications - immunology; Renal Insufficiency - immunology; Retrospective Studies; Sirolimus - therapeutic use; Toxicity: urogenital system
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2003.10.002

Calcineurin inhibitor-related renal toxicity affects patient and graft survival in transplant recipients. Our clinical experience has revealed sirolimus to be an effective agent in treating renal insufficiency related to calcineurin inhibitor toxicity. We performed a retrospective review of the medical records of OLT recipients suffering from chronic renal insufficiency and treated with sirolimus at the University of Miami. Fourteen patients (nine men and five women) of mean age 57 years who had been treated with tacrolimus for at least 30 days were converted to sirolimus after developing nephrotoxicity. Mean creatinine clearances collected on day 0, 30, 60, and 90 after conversion were 40.1 mL/min, 49.6 mL/min, 53.9 mL/min, and 51.4 mL/min, respectively. Episodes of acute cellular rejection were not increased during the sirolimus conversion. This retrospective review suggests that OLT patients suffering from tacrolimus-related renal insufficiency successfully converted to sirolimus may benefit from this therapy.